Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152619 · ClinicalTrials.gov registry record · Phase 1
A Study of RO4989991 in Patients With Allergic Rhinitis
A Phase 1 study of Asthma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT01152619: Completed Phase 1 study of Asthma, sponsored by Hoffmann-La Roche.
NCT01152619 is a Phase 1 study of Asthma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 24 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01152619, a Phase 1 study of Asthma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO4989991
Study Locations (4)
Florida
- - South Miami
Illinois
- - Normal
North Carolina
- - Raleigh
South Carolina
- - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
What the finished NCT01152619 record still lists
NCT01152619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01152619 reports a single indexed study location in Florida, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01152619 about?
NCT01152619 is a clinical study titled "A Study of RO4989991 in Patients With Allergic Rhinitis". This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.
What is the current status of trial NCT01152619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-07. Estimated completion is 2011-02.
What conditions does trial NCT01152619 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01152619?
The interventions under investigation include: Placebo (DRUG), RO4989991 (DRUG).
Who is sponsoring clinical trial NCT01152619?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01152619 being conducted?
This trial has 4 study locations across Florida, Illinois, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01152619's enrollment target sits among peer trials
24 326th of 374 higher than 47 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia